is that INSM "will" get an extension. Reason? Recent shift in NSDQ policy in dealing with companies in INSM's type predicament. Indeed, INSM is even getting advice from the former NSDQ General Counsel.
So INSM must
1. Request a Hearing by July 19th, or 7 days from NSDQ letter
2. Attend hearing in mid to late July and request extension
3. Present a clear business plan for success
Why do they think NSDQ will go along? There has been a recent policy shift in the last few weeks towards leniency when dealing with companies who meet all other criteria for listing other than Share Price.
How's that for DD?
Who were the 1 star posters here?
This is 100% factual post with 0% opinion. It is relevant and a good discussion point.
Pumper losers is the only answer I come up with. Penny, Kevie, Historian, others, thoughts?
P.S. Kevie, you can ignore me. I don't want your opinion.
Jan 2, 2003 $0.48 33,186,336
Jan 2, 2004 $3.03 38,394,994
Jan 3, 2005 $2.30 44,893,496
Jan 3, 2006 $2.13 66,525,792
Jan 3, 2007 $0.90 101,328,118
Jan 2, 2008 $0.83 121,820,000
Jan 1, 2009 ????????????????????????
That is really old news to most. The likelyhood of the extension doesn't change because Allan and Ritchie said so plus it is costing shareholders to pay a consultant to help with a delisting appeal. Too funny.
Delisting aside, it tells you no FOB partner near term.
No, doesn't tell me any such thing!
Here's some French for you:
Deux études sur la Mexiletine (ou Mexitil chez nous) plutôt encourageantes pour les problèmes de myotonie.
L!Université de Rochester (USA) met beaucoup d!espoir dans une nouvelle molécule appelée Iplex et essayée sur 6 patients. Les résultats sur l'état général de ces malades semblent très encourageants.
Which one of these 2 products has succeeded since?